Related Experiment Videos
Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors
Maurice Phil DeYoung1, Matthew Tress, Ramaswamy Narayanan
1Center for Molecular Biology and Biotechnology and Department of Biology, Florida Atlantic University, 777 Glades Road, Boca Raton, FL 33431, USA.
Abstract:
We report here a cancer drug therapy use of a gene involved in Down's syndrome. Using bioinformatics approaches, we recently predicted Single Minded 2 gene (SIM2) from Down's syndrome critical region to be specific to certain solid tumors. Involvement of SIM2 in solid tumors has not previously been reported. Intrigued by a possible association between a Down's syndrome gene and solid tumors, we monitored SIM2 expression in solid tumors. Isoform-specific expression of SIM2 short-form (SIM2-s) was seen selectively in colon, prostate, and pancreatic carcinomas but not in breast, lung, or ovarian carcinomas nor in most normal tissues. In colon tumors, SIM2-s expression was seen in early stages. Antisense inhibition of SIM2-s expression in a colon cancer cell line caused inhibition of gene expression, growth inhibition, and apoptosis. The administration of the antisense, but not the control, oligonucleotides caused a pronounced inhibition of tumor growth in nude mice with no major toxicity. Our findings provide a strong rationale for the genes-to-drugs paradigm, establish SIM2-s as a molecular target for cancer therapeutics, and may further understanding of the cancer risk of Down's syndrome patients.
Insights
A gene linked to Down's syndrome, Single Minded 2 short-form (SIM2-s), shows promise as a cancer drug target. Inhibiting SIM2-s in colon cancer cells and tumors reduced growth and induced cell death, suggesting therapeutic potential.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The Single Minded 2 gene (SIM2) from the Down's syndrome critical region was computationally predicted to be specific to certain solid tumors.
- The involvement of SIM2 in solid tumor development has not been previously reported.
Purpose of the Study:
- To investigate the expression of SIM2 in various solid tumors and assess its potential as a molecular target for cancer therapy.
- To evaluate the therapeutic efficacy of inhibiting SIM2 short-form (SIM2-s) expression in preclinical cancer models.
Main Methods:
- Bioinformatics analysis was used to predict SIM2 specificity in solid tumors.
- SIM2 expression was monitored in various human carcinoma cell lines and tumor tissues.
- Antisense oligonucleotides were used to inhibit SIM2-s expression in a colon cancer cell line and in vivo tumor models.
Main Results:
- SIM2 short-form (SIM2-s) expression was selectively detected in colon, prostate, and pancreatic carcinomas, and notably in early-stage colon tumors.
- Antisense inhibition of SIM2-s led to suppressed gene expression, growth inhibition, and apoptosis in colon cancer cells.
- Administration of antisense oligonucleotides significantly inhibited tumor growth in nude mice with no major observed toxicity.
Conclusions:
- SIM2-s is a promising molecular target for developing novel cancer therapeutics.
- Targeting SIM2-s aligns with the genes-to-drugs paradigm and may offer insights into the cancer risk associated with Down's syndrome.
- These findings support the development of SIM2-s-targeted therapies for specific solid tumors.